Autolus Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 2/6
Autolus Therapeutics is forecast to grow earnings and revenue by 49.1% and 55.5% per annum respectively. EPS is expected to grow by 55.7% per annum. Return on equity is forecast to be -193.6% in 3 years.
Anahtar bilgiler
49.1%
Kazanç büyüme oranı
55.7%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 27.1% |
| Gelir büyüme oranı | 55.5% |
| Gelecekteki özkaynak getirisi | -193.6% |
| Analist kapsamı | Good |
| Son güncelleme | 02 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
Sep 06Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?
Aug 15
Autolus Therapeutics: Major Inflection Point On The Horizon
Jul 31Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
May 14We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely
Nov 06Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Jun 26We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth
Mar 09Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?
Dec 12Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy
Oct 12Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching
Aug 17Autolus Therapeutics Q2 2022 Earnings Preview
Aug 03Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation
Apr 19We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully
Dec 15Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 175 | -91 | -62 | -43 | 6 |
| 12/31/2025 | 61 | -183 | -137 | -134 | 8 |
| 12/31/2024 | 15 | -208 | -189 | -137 | 8 |
| 6/30/2024 | 10 | -234 | -161 | -157 | N/A |
| 3/31/2024 | 10 | -221 | -152 | -144 | N/A |
| 12/31/2023 | 2 | -208 | -157 | -146 | N/A |
| 9/30/2023 | 6 | -158 | -145 | -135 | N/A |
| 6/30/2023 | 7 | -155 | -142 | -127 | N/A |
| 3/31/2023 | 7 | -152 | -133 | -120 | N/A |
| 12/31/2022 | 6 | -149 | -123 | -112 | N/A |
| 9/30/2022 | 3 | -164 | -119 | -107 | N/A |
| 6/30/2022 | 1 | -155 | -119 | -110 | N/A |
| 3/31/2022 | 2 | -146 | -123 | -116 | N/A |
| 12/31/2021 | 2 | -142 | -127 | -118 | N/A |
| 9/30/2021 | 3 | -143 | -149 | -136 | N/A |
| 6/30/2021 | 3 | -147 | -154 | -141 | N/A |
| 3/31/2021 | 2 | -145 | -145 | -131 | N/A |
| 12/31/2020 | 2 | -142 | -132 | -118 | N/A |
| 9/30/2020 | 2 | -140 | -134 | -123 | N/A |
| 6/30/2020 | 1 | -130 | -120 | -109 | N/A |
| 3/31/2020 | 1 | -127 | -113 | -99 | N/A |
| 12/31/2019 | 3 | -124 | -120 | -101 | N/A |
| 9/30/2019 | 3 | -104 | -109 | -88 | N/A |
| 6/30/2019 | 3 | -89 | -93 | -72 | N/A |
| 3/31/2019 | 3 | -68 | -76 | -61 | N/A |
| 12/31/2018 | 1 | -58 | -56 | -43 | N/A |
| 9/30/2018 | 1 | -45 | -41 | -32 | N/A |
| 6/30/2018 | 1 | -41 | N/A | N/A | N/A |
| 3/31/2018 | 2 | -38 | N/A | N/A | N/A |
| 12/31/2017 | 2 | -29 | N/A | N/A | N/A |
| 9/30/2017 | 2 | -20 | N/A | -16 | N/A |
| 9/30/2016 | 1 | -13 | N/A | -10 | N/A |
| 9/30/2015 | 0 | -7 | N/A | -3 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: AUTL is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: AUTL is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: AUTL is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: AUTL's revenue (55.5% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: AUTL's revenue (55.5% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: AUTL is forecast to be unprofitable in 3 years.